OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

In a regulatory filing, Opko Health (OPK) disclosed that its CEO Phillip Frost bought 200K shares of common stock on March 17th in a total ...

We recently compiled a list of the 10 Best Stocks Under $3 to Buy Now. In this article, we are going to take a look at where OPKO Health, Inc. (NASDAQ:OPK) stands against the other stocks under $3.

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

To our collaborators, especially, the formidable team at OPKO Health, Inc., we are grateful for your partnership and the opportunity to expand our N-Tab™ platform to additional high value ...

OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and ...